This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 Mar 22;361(9362):1060.

doi: 10.1016/S0140-6736(03)12813-9.

Maintaining linguistic standards

PMID: 12660091
DOI: 10.1016/S0140-6736(03)12813-9

Comment

Maintaining linguistic standards

John R C Logie. Lancet. 2003.

. 2003 Mar 22;361(9362):1060.

doi: 10.1016/S0140-6736(03)12813-9.

Author

PMID: 12660091
DOI: 10.1016/S0140-6736(03)12813-9

No abstract available

PubMed Disclaimer

Comment on

Tamoxifen for breast cancer among hysterectomised women.
Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P; Italian Tamoxifen Study Group. Veronesi U, et al. Lancet. 2002 Mar 30;359(9312):1122-4. doi: 10.1016/S0140-6736(02)08159-X. Lancet. 2002. PMID: 11943263 Clinical Trial.
Tamoxifen for breast cancer in hysterectomised women.
R Benson J. R Benson J. Lancet. 2002 Nov 30;360(9347):1784-5; author reply 1785. doi: 10.1016/s0140-6736(02)11693-x. Lancet. 2002. PMID: 12480454 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science